Immix Biopharma Inc (NASDAQ:IMMX) shares were stable first thing Wednesday after it announced preclinical data of its lead program, IMX-110.
The data showed that IMX-110 produced a 50% response rate in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin’s 0% response rate in the same mouse study.
The responses were assessed by RECIST 1.1 criteria applied to mice, with progression assessed after one treatment cycle.
The U.S. Food and Drug Administration already approved rare pediatric disease designation to IMX-110 for pediatric cancer, rhabdomyosarcoma.
CEO Ilya Rachman said, “We strive to test our drug candidates in the most realistic, challenging animal models available. We are thrilled to see that in this first-line-therapy resistant STS model that IMX-110 showed significant activity. We believe this study is a preview of what our SMARxT Platform generating Tissue-Specific Therapeutics can do, a distinct alternative to the traditional ‘single target, single mutation’ development model.”
The FDA has approved orphan drug designation for IMX-110 for the treatment of soft tissue sarcoma. The FDA has already approved rare pediatric disease designation to IMX-110 for the treatment of a life-threatening pediatric cancer in children, rhabdomyosarcoma.
IMMX shares are up $1.67, or 30.8%, to $7.10 soon after the opening bell on Wednesday.
